Eris Lifesciences Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Eris Lifesciences wird ein jährliches Gewinn- und Umsatzwachstum von 22.3% bzw. 15.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 22.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 18.8% betragen.

Wichtige Informationen

22.5%

Wachstumsrate der Gewinne

22.3%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	18.2%
Wachstumsrate der Einnahmen	16.1%
Zukünftige Eigenkapitalrendite	19.0%
Analystenabdeckung	Good
Zuletzt aktualisiert	12 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Aug 05

Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

May 24

Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report

Feb 15

Recent updates

Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why

Sep 19

Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 27%

Sep 03

Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Aug 05

Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Aug 04

Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)

Jul 13

Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

May 24

Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price

May 10

An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued

Mar 14

Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report

Feb 15

Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)

Dec 28

Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Dec 07

Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Nov 11

Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Jul 20

Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?

Nov 20

These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely

Jun 20

A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)

Feb 24

Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?

Dec 28

Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today

Sep 23

If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late

May 26

Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate

Apr 17

Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?

Mar 12

Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?

Feb 25

Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar

Feb 12

Eris Lifesciences Limited (NSE:ERIS) Analysts Are Pretty Bullish On The Stock After Recent Results

Jan 30

Read This Before Buying Eris Lifesciences Limited (NSE:ERIS) Shares

Jan 17

Our View On Eris Lifesciences' (NSE:ERIS) CEO Pay

Dec 30

Is Eris Lifesciences Limited's (NSE:ERIS) Recent Performance Tethered To Its Attractive Financial Prospects?

Dec 10

Eris Lifesciences (NSE:ERIS) Shareholders Booked A 25% Gain In The Last Year

Nov 23

Is It Worth Buying Eris Lifesciences Limited (NSE:ERIS) For Its 1.1% Dividend Yield?

Oct 22

Gewinn- und Umsatzwachstumsprognosen

NSEI:ERIS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (INR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2027	38,162	7,158	9,451	N/A	6
3/31/2026	34,252	5,608	8,466	N/A	9
3/31/2025	30,299	3,937	-10,353	N/A	8
6/30/2024	22,469	3,803	N/A	N/A	N/A
3/31/2024	19,913	3,920	3,568	4,860	N/A
12/31/2023	18,406	3,864	N/A	N/A	N/A
9/30/2023	17,750	3,856	-3,302	4,446	N/A
6/30/2023	17,298	3,824	N/A	N/A	N/A
3/31/2023	16,618	3,822	-5,497	2,917	N/A
12/31/2022	15,663	3,970	N/A	N/A	N/A
9/30/2022	14,766	3,959	419	2,844	N/A
6/30/2022	13,746	3,940	N/A	N/A	N/A
3/31/2022	13,262	4,061	2,572	3,783	N/A
12/31/2021	12,993	3,941	N/A	N/A	N/A
9/30/2021	12,763	3,834	4,058	4,428	N/A
6/30/2021	12,482	3,728	N/A	N/A	N/A
3/31/2021	11,926	3,551	3,496	3,754	N/A
12/31/2020	11,625	3,432	N/A	N/A	N/A
9/30/2020	11,192	3,165	1,211	2,724	N/A
6/30/2020	10,744	3,015	N/A	N/A	N/A
3/31/2020	10,582	2,965	1,199	2,712	N/A
12/31/2019	10,252	2,943	N/A	N/A	N/A
9/30/2019	10,119	3,110	2,219	2,599	N/A
6/30/2019	9,920	3,036	N/A	N/A	N/A
3/31/2019	9,672	2,908	1,850	2,230	N/A
12/31/2018	9,851	2,925	N/A	N/A	N/A
9/30/2018	9,442	2,870	N/A	N/A	N/A
6/30/2018	9,212	2,945	N/A	N/A	N/A
3/31/2018	8,196	2,941	N/A	2,346	N/A
12/31/2017	8,026	2,800	N/A	N/A	N/A
9/30/2017	7,781	2,735	N/A	N/A	N/A
6/30/2017	7,277	2,505	N/A	N/A	N/A
3/31/2017	7,205	2,468	N/A	2,002	N/A
3/31/2016	5,967	1,112	N/A	1,315	N/A
3/31/2015	5,456	892	N/A	901	N/A
3/31/2014	5,088	704	N/A	896	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ERISDas prognostizierte Gewinnwachstum (17.6% pro Jahr) liegt über der Sparquote (6.7%).

Ertrag vs. Markt: ERISDie Erträge des Unternehmens (17.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (16% pro Jahr).

Hohe Wachstumserträge: ERISEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: ERISDie Einnahmen des Unternehmens (15.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (10% pro Jahr).

Hohe Wachstumseinnahmen: ERISDie Einnahmen des Unternehmens (15.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: ERISDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (18.8%).

Eris Lifesciences Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 7.3% to ₹1,334

Price target increased by 12% to ₹1,243

Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Consensus revenue estimates increase by 12%, EPS downgraded

Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report

Recent updates

Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why

Price target increased by 7.3% to ₹1,334

Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 27%

Price target increased by 12% to ₹1,243

Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Eris Lifesciences Limited, Annual General Meeting, Sep 25, 2024

Eris Lifesciences Limited to Report Q1, 2025 Results on Aug 02, 2024

Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)

Now 5.9% overvalued after recent price rise

Now 20% overvalued after recent price rise

Eris Lifesciences Limited (NSEI:ERIS) completed the acquisition of additional 19% stake in Swiss Parenterals Limited from Amit Indubhushan Bakshi, Inderjeet Singh Negi, Kaushal Kamlesh Shah and Rajendra Rambhai Patel.

Consensus revenue estimates increase by 12%, EPS downgraded

Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Eris Lifesciences Limited to Report Q4, 2024 Results on May 21, 2024

Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price

An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued

Now 20% undervalued after recent price drop

Eris Lifesciences Limited (NSEI:ERIS) completed the acquisition of 51% stake in Swiss Parenterals Limited.

Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report

Eris Lifesciences Limited (NSEI:ERIS) agreed to acquire 51% stake in Swiss Parenterals Limited INR6.4 billion.

Third quarter 2024 earnings released: EPS: ₹7.55 (vs ₹7.49 in 3Q 2023)

Eris Lifesciences Limited to Report Q3, 2024 Results on Feb 13, 2024

Insufficient new directors

Now 22% overvalued after recent price rise

Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)

Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Eris Lifesciences Limited (NSEI:ERIS) entered into a definitive agreement to acquire Dermatology and Nephrology branded formulations business units of Biocon Biologics for INR 3.7 billion.

Second quarter 2024 earnings: EPS exceeds analyst expectations

Eris Lifesciences Limited to Report Q2, 2024 Results on Nov 08, 2023

Insider recently sold ₹1.6m worth of stock

New major risk - Dividend sustainability

Eris Lifesciences Limited, Annual General Meeting, Sep 25, 2023

First quarter 2024 earnings released: EPS: ₹6.97 (vs ₹6.96 in 1Q 2023)

Eris Lifesciences Limited to Report Q1, 2024 Results on Aug 07, 2023

Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Full year 2023 earnings: EPS misses analyst expectations

Eris Lifesciences Limited to Report Q4, 2023 Results on May 17, 2023

Chairman & MD recently bought ₹7.2m worth of stock

Chairman & MD recently bought ₹128m worth of stock

Eris Lifesciences Limited (NSEI:ERIS) acquired dermatology portfolio of Glenmark Pharmaceuticals Limited from Glenmark Pharmaceuticals Limited (NSEI:GLENMARK) for Rs 3.4 billion.

Third quarter 2023 earnings released: EPS: ₹7.49 (vs ₹7.41 in 3Q 2022)

Eris Lifesciences Limited to Report Q3, 2023 Results on Jan 17, 2023

Chairman & MD recently bought ₹109m worth of stock

Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?

High number of new directors

Second quarter 2023 earnings released: EPS: ₹8.84 (vs ₹8.71 in 2Q 2022)

Eris Lifesciences Limited to Report First Half, 2023 Results on Oct 20, 2022

Insider recently sold ₹2.4m worth of stock

Now 21% undervalued

First quarter 2023 earnings released: EPS: ₹6.96 (vs ₹7.86 in 1Q 2022)

Eris Lifesciences Limited Declares Interim Dividend for the Financial Year 2022-2023, Payable on or Before 04 September 2022

Eris Lifesciences Limited to Report Q1, 2023 Results on Aug 05, 2022

Less than half of directors are independent

Eris Lifesciences Limited Announces Resignation of Vijaya Sampath as Independent Director

These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely

Eris Lifesciences Limited, Annual General Meeting, Sep 01, 2022

Insider recently sold ₹2.1m worth of stock

Eris Lifesciences Limited (BSE:540596) agreed to acquire Oaknet Healthcare Private Limited for INR 6.5 billion.

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?

Insider recently sold ₹1.7m worth of stock

Second quarter 2022 earnings released: EPS ₹8.71 (vs ₹7.93 in 2Q 2021)

Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today